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Predominant effect of kidney disease on mortality in Pima In-
dians with or without type 2 diabetes.
Background. We examined the effect of kidney disease (KD)
on mortality in nondiabetic and diabetic Pima Indians aged ≥45
years old.
Methods. Deaths and person-years of follow-up were strati-
fied in a time-dependent fashion into categories of (1) no pro-
teinuria and normal serum creatinine (SCr); (2) proteinuria and
normal SCr; (3) high SCr [SCr ≥133 lmol/L (1.5 mg/dL) in men,
≥124 lmol/L (1.4 mg/dL) in women] but not on renal replace-
ment therapy (RRT); or (4) RRT.
Results. Among 1993 subjects, 55.8% had type 2 diabetes
at baseline. Overall death rates increased with declining kid-
ney function in both the nondiabetic and diabetic subjects
(P < 0.0001). Death rates were similar in nondiabetic and di-
abetic subjects with comparable levels of kidney function, al-
though the number of deaths among nondiabetic subjects with
advanced KD was small. Infections and malignancy were the
leading causes of death in nondiabetic subjects with KD. Among
diabetic subjects, overall mortality increased with diabetes du-
ration (P = 0.0001) and was highest in those on RRT (P <
0.0001). High SCr was associated with higher death rates from
cardiovascular disease (CVD), diabetic nephropathy (DN), in-
fections, and malignancy.
Conclusion. Death rates increased comparably with worsen-
ing kidney function in both nondiabetic and diabetic subjects
and were similar in nondiabetic and diabetic subjects without
KD. KD was associated with excess mortality from DN, CVD,
infections, and malignancy in diabetic subjects, and from infec-
tions in those without diabetes.
Chronic kidney disease, defined as kidney damage or
decreased kidney function for 3 or more months, affects
11% of the United States (US) population [1], and it is
associated with increased mortality from cardiovascular
Key words: Pima Indians, kidney disease, type 2 diabetes, mortality.
Received for publication November 24, 2004
and in revised form February 18, 2005, and April 4, 2005
Accepted for publication April 21, 2005
C© 2005 by the International Society of Nephrology
disease (CVD) and end-stage renal disease. Chronic kid-
ney disease is twice as frequent in persons with diabetes,
and those with diabetes also have the highest burden of
comorbidities and the lowest survival [2]. Native Ameri-
cans, African Americans, and Hispanics with diabetes are
at particularly high risk of developing kidney failure [3],
a factor that may influence mortality patterns in these
populations.
In this study we examined the impact of kidney dis-
ease (KD), defined by proteinuria, elevated serum creati-
nine concentration, or onset of renal replacement therapy
(RRT), on overall and cause-specific mortality in nondi-
abetic and diabetic Pima Indians from the Gila River In-
dian Community in Arizona. This population has a high
incidence of type 2 diabetes [4], and the incidence of kid-
ney failure attributable to type 2 diabetes is 14 times that
of the US diabetic population aged 45 to 64 years [5].
METHODS
Patients and study design
The Pima Indians and the closely related Tohono
O’odham (Papago) Indians who live in the Gila River
Indian Community in the desert of central Arizona par-
ticipate in a comprehensive longitudinal study of diabetes
and its complications. Since 1965, each member of this
community who is ≥5 years of age is invited to have a re-
search examination approximately every 2 years, regard-
less of health. These biennial examinations include mea-
surements of venous plasma glucose, obtained 2 hours
after a 75 g oral glucose load, and assessment of the
complications of diabetes. Protein and creatinine con-
centrations are measured in urine specimens collected
at the end of the 2-hour glucose tolerance test. Among
those with at least a trace of protein in the urine by dip-
stick, urine protein concentration is determined quan-
titatively by the Shevky-Stafford acid/alcohol precipita-
tion method [6]. The urine protein forms precipitates
upon the addition of Tsuchiya’s reagent. The resulting
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Table 1. Baseline clinical and demographic features of Pima Indians aged ≥45 years old
Nondiabetic subjects Diabetic subjects
(N = 880) a (N = 1359)a
Mean ± SD Centilesb Mean ± SD Centilesb
Age years 53.4 ± 10.0 46.3–57.8 53.2 ± 8.5 46.6–57.9
Duration of diabetes years – – 7.0 ± 7.2 0.4–11.7
Mean arterial pressure mm Hg 96.9 ± 14.1 86.7–105.3 100.3 ± 15.3 90.0–108.7
BMI kg/m2
Men 29.2 ± 6.1 25.0–32.0 30.7 ± 5.9 26.8–33.6
Women 33.5 ± 7.4 28.3–37.3 33.6 ± 7.2 28.4–37.0
Serum cholesterol mg/dL 182.2 ± 37.2 158.0–204.0 188.5 ± 46.2 159.0–212.0
2-hour plasma glucose mg/dL 122.9 ± 31.5 100.0–145.0 335.9 ± 123.7 229.5–428.0
Serum creatinine mg/dL 0.8 ± 0.3 0.7–0.9 0.8 ± 0.5 0.6–0.9
Baseline data were missing for mean arterial pressure in 19 nondiabetic and 12 diabetic subjects, for 2-hour plasma glucose in 15 nondiabetic and 162 diabetic subjects,
for BMI in 15 nondiabetic and 21 diabetic subjects, and for cholesterol in 2 diabetic subjects.
aTwo hundred forty-six of the nondiabetic subjects developed diabetes during the follow-up. The baseline characteristics from their first nondiabetic and first diabetic
examination are included in the table.
bThe 25th and 75th centiles.
precipitate is centrifuged (Forma Scientific, Inc., Mari-
etta, GA, USA) at a speed of 1900 to 2000 rpm (rel-
ative centrifugal force of 990) for 10 minutes and then
measured. Serum and urine creatinine concentrations
are measured by a modification of the Jaffe´ reaction
[7]. Proteinuria was defined by a protein-to-creatinine
ratio ≥0.5 g protein/g creatinine, reflecting an approx-
imate protein excretion rate of at least 0.5 g/day. Dia-
betes was diagnosed by World Health Organization cri-
teria [8] and the date of diagnosis was determined from
these research examinations or from review of clinical
records if diabetes was diagnosed in the course of rou-
tine medical care. The onset of RRT was defined as the
date of beginning chronic dialysis and was ascertained
independently of the research examinations. The study
population included subjects who were at least half-Pima
or Tohono O’odham heritage, resided in the commu-
nity between January 1, 1965 and December 31, 2001
and had 1 or more research examinations after 45 years
of age. Each subject’s vital status as of December 31,
2001 was determined. For all deaths, the accuracy and
completeness of the underlying cause was determined
by review of clinical records, autopsy reports, and death
certificates.
Terminology and codes of the International Classifica-
tion of Disease, Ninth Revision (ICD-9) were used for
recording causes of death. Deaths were considered natu-
ral if they were due to disease (ICD-9 codes 001.0–799.9)
and external if they were due to injury or poisoning (ICD-
9 codes 800.0–999.9). The underlying cause of death was
coded as diabetic nephropathy (ICD-9 code 250.4) in sub-
jects who had kidney failure attributable to diabetes if
they (1) did not receive RRT, (2) received RRT incon-
sistently or discontinued RRT, or (3) had dialysis-related
complications as an immediate or contributory cause of
death (e.g., malnutrition, shock, heart failure, septicemia,
pericarditis, hypokalemia).
Statistical analysis
Death rates were calculated as the number of sub-
jects who died per 1000 person-years of follow-up. The
period of risk began at the first research examination
after attaining the age of 45 years and extended until
death or December 31, 2001, whichever came earlier. In
subjects who did not have diabetes at the beginning of
follow-up and developed diabetes during the course of
the study, their person-time at risk was computed sepa-
rately for each status. Follow-up within the nondiabetic
and diabetic person-time strata was stratified in a time-
dependent fashion according to decades of age and the
following kidney function categories: normal SCr and no
proteinuria; proteinuria (protein-to-creatinine ratio ≥0.5
g protein/g creatinine) with normal SCr; high SCr [serum
creatinine ≥133 lmol/L (1.5 mg/dL) in men, ≥124 lmol/L
(1.4 mg/dL) in women], with or without proteinuria, but
not receiving RRT; receiving RRT.
Age- and sex-adjusted death rates and death rate ratios
(DRR) were examined according to these categories and
were standardized to the 1985 Pima Indian population
aged 45 years and over. Tests for general association were
computed by the Mantel-Haenszel test [9] and for linear
association by the Mantel extension test [10].
RESULTS
During a median follow-up of 11.0 years (range 0.06–
36.8), 332 deaths occurred among the 634 subjects who
were nondiabetic throughout follow-up, and 709 deaths
occurred among 1359 subjects who were diabetic at
baseline (N = 1113) or developed diabetes during the
study period (N = 246). Baseline characteristics of the
study population at the first nondiabetic and diabetic ex-
aminations are presented in Table 1. At baseline, 848
nondiabetic subjects had normal kidney function and 32
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Table 2. The number of nondiabetic and diabetic subjects according to baseline kidney function and progression or regression of kidney function
at the last examination
Kidney function at first nondiabetic examination Normal Proteinuria High SCr RRT Total at last examination
Normal 823 7 0 0 830
Kidney function at last nondiabetic examination Proteinuria 18 15 1 0 34
High SCr 4 0 3 0 7
RRT 3 0 6 0 9
Total 848 22 10 0 880
Kidney function at first diabetic examination
Normal Proteinuria High SCr RRT Total at last examination
Kidney function at end of follow-up Normal 796 10 0 0 806
Proteinuria 148 109 1 0 258
High SCr 28 21 28 0 77
RRT 122 68 25 3 218
Total 1094 208 54 3 1359
Subjects with stable kidney function neither worsened nor improved their kidney function (bold numbers). In each column, the numbers below the bold number
represent subjects with worsening kidney function, whereas those above the bold number represent subjects who had improved kidney function.
had KD (proteinuria, high SCr, or RRT). At the end
of nondiabetic follow-up, 841 (95.6%) of these subjects
remained in the same category of kidney function, 31
(3.5%) worsened to more severe kidney disease and 8
(0.9%) improved their kidney function (Table 2). Among
diabetic subjects, 1094 had normal kidney function and
265 had KD at baseline. Of these, 936 (68.9%) remained
in the same kidney function category at the end of the
study period, whereas 412 (30.4%) subjects progressed
to more severe kidney disease and 11 (0.8%) improved.
The age- and sex-adjusted death rates from natural
causes in nondiabetic subjects ranged from 23.8/1000
person-years (95% CI 20.8–26.8) in those without kidney
disease to 84.5/1000 person-years (95% CI 1.6–167.4) in
subjects with high SCr (P < 0.0001) (Table 3). The range
among diabetic subjects with comparable degrees of kid-
ney disease was similar, rising from 25.3/1000 person-
years (95%CI 22.3–28.2) in subjects with normal kid-
ney function, to 105.1/1000 person-years (95% CI 75.7–
134.5) in those with high SCr (Table 3). With progression
to RRT, the death rate increased further to 208.7/1000
person-years (95%CI 171.1–246.3) in those with diabetes
(P < 0.0001). With only 9 nondiabetic subjects on RRT
during 28.4 person-years of follow-up, insufficient data
were available to compute an age- and sex-adjusted death
rate in this category. Although the number of deaths in
nondiabetic subjects with KD was small, the excess mor-
tality was due primarily to higher death rates from infec-
tions. On the other hand, diabetic subjects with protein-
uria had higher age- and sex-adjusted death rates from
DN, infections, and CVD. Those with high SCr also had
increased mortality due to malignant neoplasms. In both
nondiabetic and diabetic subjects, age- and sex-adjusted
death rates for other underlying causes did not differ sig-
nificantly across the kidney function groups.
The major underlying infectious cause of death among
subjects, regardless of the presence or absence of kidney
disease, was pneumonia, accounting for 62% of deaths
from infectious diseases in those without diabetes and
51% of deaths from infectious diseases in those with
diabetes. Deaths from malignant neoplasms in diabetic
subjects with kidney disease were too few (12 in the
proteinuria group, 8 in the high SCr group, 2 in RRT
group) to reliably determine trends by types of neo-
plasms. Nevertheless, in those receiving RRT, the 2 deaths
from malignancy were attributed to neoplasms of the
kidney.
Figure 1 shows a strong effect of kidney function on
natural and CVD mortality in all categories of diabetes
duration, but a lesser effect of duration for any category
of kidney function. The higher overall mortality in those
with longer duration of diabetes is due primarily to the
greater proportion of person-years of follow-up falling
in the categories of worse kidney function, as shown in
Figure 1C.
DISCUSSION
Overall mortality in Pima Indians was greater with
greater severity of kidney disease in both nondiabetic
and diabetic subjects. The death rates in nondiabetic and
diabetic subjects without kidney disease were virtually
identical and increased to a similar degree with worsen-
ing kidney function in both groups, suggesting that kidney
disease rather than diabetes per se is the major determi-
nant of increased mortality among the diabetic popula-
tion.
Cardiovascular disease was the leading cause of death
in diabetic Pima Indians without kidney disease and in
those with early kidney disease characterized by protein-
uria. With progression of KD, CVD mortality increased
further, but became the second leading cause of death be-
hind DN. The greatest increase in CVD deaths occurred
in subjects receiving RRT, in whom the death rate was 9
times as high as in those with normal kidney function. In-
deed, the introduction and widespread use of RRT, while
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Fig. 1. Trends in age- and sex-adjusted death
rates from natural causes (A) and cardiovas-
cular disease (CVD) (B). The bars represent
mortality rates stratified by diabetes and its
duration in the 4 kidney function categories.
The line shows overall death rates by diabetes
and its duration. Overall mortality rates were
positively associated with duration of diabetes
and were similar in the nondiabetic subjects
and those with diabetes of <10 years’ dura-
tion. Panel (C) is a frequency distribution of
person-years stratified by diabetes and its du-
ration in the 4 kidney function categories. The
fraction of person-years of follow-up among
persons with normal kidney function ranged
from 96% in nondiabetic subjects to 53% in
those with 20 to 30 years of diabetes. Con-
versely, the fraction of person-years among
persons on renal replacement therapy (RRT)
ranged from 0.4% in nondiabetic subjects to
12% in those with 20 to 30 years of diabetes.
¶Rate is null; ∗insufficient data.
prolonging life and reducing deaths that would otherwise
be attributable to DN, is largely responsible for the rise in
deaths from cardiovascular disease in diabetic Pima Indi-
ans [11]. These findings extend our previous observation
[12] that overall mortality in diabetic Pima Indians with
clinical proteinuria was 3.5 times as high as in those with-
out proteinuria, with the excess largely attributable to
uremia and to cardiovascular disease.
Although SCr is not an ideal measurement of kid-
ney function, the association between SCr concen-
tration and mortality has been reported in several
other studies. The choice of cut points, although arbi-
trary, was made to ensure that we identified an ad-
vanced stage of kidney disease. Alternative cut points
did not change the overall conclusions of the study
(data not shown).
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The NHANES I study [13] found that diabetic per-
sons with moderate renal insufficiency [SCr of 122 to
177 lmol/L (1.4 to 2.0 mg/dL) in men and 104 to 146
lmol/L (1.2 to 1.7 mg/dL) in women] had higher total
and CVD mortality than those without diabetes or renal
insufficiency. There was, however, no significant associ-
ation between serum creatinine and total or cardiovas-
cular mortality in this population after adjustment for
cardiovascular risk factors such as sex, age, hypercholes-
terolemia, hypertension, diabetes, and smoking. Hence,
the authors suggested that the association between renal
insufficiency and cardiovascular disease reported in other
studies [14–17], some of which excluded subjects with di-
abetes, was due to the co-occurrence of other established
cardiovascular risk factors. The authors proposed that
elevated serum creatinine was simply a marker for the
presence of these risk factors. Similarly, in the Framing-
ham community-based study [18], mild renal insufficiency
[SCr of 136 to 265 lmol/L (1.5 to 3.0 mg/dL) in men and
120 to 265 lmol/L (1.4 to 3.0 mg/dL) in women] was as-
sociated with higher total mortality in men, but there was
no association of KD with age-adjusted cardiovascular
mortality in either sex. On the other hand, the risk of
death in the US Medicare population aged 65 years and
older [19] with chronic KD but no diabetes was 11 times
as high as the risk of progression to RRT, and 6 times
as high as the risk of RRT for those with both diabetes
and chronic KD. Likewise, in the ARIC study [20], the
higher CVD incidence in middle-aged nondiabetic and
diabetic patients with KD was strongly associated with
risk factors that were more prevalent as GFR declined.
The NHANES II Mortality Study [21] found a graded
relationship between proteinuria and the risk of total or
CVD mortality in diabetic as well as nondiabetic subjects.
In NHANES II, CVD mortality was highest among those
with glomerular filtration rate (GFR) <70 mL/min. These
findings suggest that higher mortality associated with KD
reflects increased rates of CVD.
The independent, inverse association between esti-
mated GFR, computed from a formula described in the
Modification of Diet in Renal Disease study (MDRD for-
mula) [22], and mortality rates from CVD was confirmed
by recent studies in 2 different populations. In a large, eth-
nically diverse outpatient sample of the adult population
in the San Francisco Bay Area [23], independent associa-
tions were found between lower estimated GFR and risk
of cardiovascular events and death from CVD. Similarly,
among patients with a previous acute myocardial infarc-
tion enrolled in the VALIANT study [24], lower GFR
was associated with higher rates of death or recurrent car-
diovascular events. Nonetheless, the MDRD formula has
not been validated in diabetic kidney disease or in ethnic
groups other than Caucasian and African Americans and
may be less accurate in persons with normal kidney func-
tion [25]. The MDRD formula was developed from mea-
sures of GFR in people with GFR <60 mL/min/1.73m2
so its use is not recommended by the National Kidney
Foundation in those with GFR ≥60 mL/min/1.73m2 [26].
Therefore, we chose to define stages of kidney function
by SCr concentration and level of urinary protein excre-
tion and not by the estimated GFR. When we analyzed
the data using the estimated GFR instead of SCr con-
centration to define kidney disease, however, the overall
conclusions of the study did not change.
By contrast to other populations, Pima Indians have
a low incidence of fatal CVD, particularly among those
without diabetes [27]. The absence of an association be-
tween KD and CVD mortality in nondiabetic Pima Indi-
ans may be due in part to the small number of nondiabetic
subjects with KD. Among diabetic Pima Indians, CVD
mortality is strongly related to diabetes duration, and di-
abetic Pima Indians with KD are more likely to die from
CVD after the onset of kidney failure, when cardiovascu-
lar risk factors, including dyslipidemia and hypertension,
become more prevalent or worsen [28].
The increased frequency of infections in subjects with
KD is related to comorbidity and to depressed humoral
and cellular immunity that progresses during the devel-
opment of uremia [29]. Infectious diseases accounted for
18% of all natural mortality in the nondiabetic subjects,
and 18% of these deaths occurred in those with kidney
disease. Pneumonia was the leading infectious cause of
death, accounting for 33% of deaths in nondiabetic sub-
jects with proteinuria and 67% in those with high SCr.
In the diabetic subjects, 15% of all natural mortality was
due to infectious diseases and 53% of these deaths oc-
curred in subjects with kidney disease. Pneumonia was
the leading infectious cause of death in the predialysis
patients, followed by kidney infections and skin infec-
tions. In the general US population with chronic kidney
disease, mortality due to infectious diseases is 3.2 times
as high as in those without KD [2]. Among patients with
end-stage renal disease, infectious diseases are the second
leading cause of death following CVD. Sepsis accounts
nationally for 75% of these infectious deaths, followed
by pulmonary infections and viral infections [2]. In Pima
Indians on RRT, infectious disease is the third leading
cause of death following DN and CVD. Pneumonia was
the leading infectious cause of death (34.8%), followed by
coccidioidomycosis (17.4%) and urinary tract infections
(13%).
Although some reports suggest that diabetes increases
the risk of death from several types of cancer, a relation-
ship between KD and deaths from malignant neoplasms
has not been described [30, 31]. Nevertheless, a 10-fold
higher risk of renal cell carcinoma has been reported [32]
in hemodialysis patients than in the nondialysis popula-
tion. Notably, renal cell carcinoma was the only cause of
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death from malignancies among diabetic Pima Indians on
RRT in this study.
Because the confounding and intermediate effects of
blood pressure, body mass index, serum cholesterol con-
centration, and plasma glucose concentration could not
be distinguished in this analysis, we chose not to con-
trol for them. Models that did control for these variables
changed only the point estimates and confidence inter-
vals, but not the overall conclusions of the study (data
not shown).
The level of kidney function in this study, with the
exception of RRT, was determined at research examina-
tions. The frequency of these examinations could there-
fore influence whether a subject was classified appropri-
ately at the time of death. Among those who died, all
available medical records were reviewed systematically
and elevations of serum creatinine concentration ≥2.0
mg/dL were noted. These data were not used in this anal-
ysis, however, because they were available only for those
who died. Accordingly, mortality rates in the pre-RRT
groups could be underestimated to the extent that sub-
jects who may have developed higher levels of KD were
not identified as such. Nonetheless, only 9% of the sub-
jects classified as having normal kidney function at all
exams had a serum creatinine concentration ≥2 mg/dL
in the medical record before death, suggesting that the
extent of kidney function misclassification was small.
CONCLUSION
Death rates from natural causes in nondiabetic Pima
Indians are comparable to those in diabetic Pima Indians
when rates are stratified by the level of kidney disease.
RRT occurred almost exclusively in subjects with dia-
betes, and mortality was highest in these subjects, with
deaths from diabetic nephropathy, cardiovascular dis-
ease, and infections being primarily responsible for the
excess mortality. The impact of cardiovascular disease on
mortality was highest after the onset of RRT. Prevent-
ing the onset and progression of diabetic kidney disease
would undoubtedly reduce the frequency of kidney fail-
ure, but might also reduce death rates from cardiovascu-
lar disease, infections, and malignancy in diabetic Pima
Indians.
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